Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy

PURPOSE/OBJECTIVES: Clinical trials of anti-Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein (CTLA-4) therapies have demonstrated a clinical benefit with low rates of neurologic adverse events in patients with melanoma brain metastases (MBMs). While the combined e...

Descripción completa

Detalles Bibliográficos
Autores principales: Burke, Aidan M., Carrasquilla, Michael, Jean, Walter C., Collins, Brian T., Anaizi, Amjad N., Atkins, Michael B., Gibney, Geoffrey T., Collins, Sean P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789649/
https://www.ncbi.nlm.nih.gov/pubmed/35096594
http://dx.doi.org/10.3389/fonc.2021.794615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789649/
https://www.ncbi.nlm.nih.gov/pubmed/35096594
http://dx.doi.org/10.3389/fonc.2021.794615

Ejemplares similares